Can we pull the plug on warfarin in atrial fibrillation?

Lancet

Volumn 362, Issue 9397, 2003, Pages 1686-1687

  Verheugt, Freek W A ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; CLOPIDOGREL; IDRAPARINUX; LIVER ENZYME; UNCLASSIFIED DRUG; WARFARIN; XIMELAGATRAN;

ANTICOAGULANT THERAPY; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG MONITORING; DRUG SAFETY; HEART ATRIUM FIBRILLATION; HEART INFARCTION PREVENTION; HUMAN; MEDICAL DECISION MAKING; NOTE; PHYSICIAN ATTITUDE; PRIORITY JOURNAL; SIDE EFFECT; STROKE;

EID: 0344874224     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)14880-5     Document Type: Note

References (8)

1. Adjusted dose warfarin versus low intensity, fixed dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet. 348:1996;633-638.
2. Cannegieter S.C., Rosendaal F.R., Wintzen A.R., Van der Meer F.J., Vandenbroucke J.P., Briet E. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med. 333:1995;11-17.
3. Brouwer M.A., Verheugt FWA. Oral anticoagulants in acute coronary syndromes. Circulation. 105:2002;1270-1274.
4. Cromheecke M.E., Levi M., Colly L.P., et al. Oral anticoagulation self-management and management by a specialist clinic: a randomised cross-over comparison. Lancet. 356:2000;97-102.
5. Eriksson B.I., Bergqvist D., Kälebo P., et al. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial. Lancet. 360:2002;1441-1447.
6. Wallentin L., Wilcox R.G., Weaver W.D., et al. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. Lancet. 362:2003;789-797.
7. Petersen P., Grind M., Adler J, and SPORTIF II Investigators. Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: SPORTIF II - a dose-guiding, tolerability and safety study. J Am Coll Cardiol. 41:2002;1445-1451.
8. Halperin JL. Efficacy and safety study of oral direct thrombin inhibitor ximelagatran compared with dose-adjusted warfarin in the prevention of stroke and systemic embolic events in patients with atrial fibrillation: SPORTIF V. American Heart Association Scientific Sessions, Orlando, USA, November, 2003.